Litcius/Paper detail

Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression

Antonio Flores‐Burgess, Carmelo Millón, Belén Gago, Laura García-Durán, Noelia Cantero-García, Araceli Puigcerver, José Ángel Narváez, Kjell Fuxé, Luis J. Santín, Zaida Dı́az-Cabiale

2021The International Journal of Neuropsychopharmacology16 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Selective serotonergic reuptake inhibitors, including fluoxetine (FLX), are the most commonly used for the treatment of major depression. However, they are effective for remission in only 30% of patients. Recently, we observed that Galanin (1-15) [GAL(1-15)] enhanced the antidepressant effects of FLX in naïve animals, suggesting a new augmentation strategy in depression. METHODS: We have analyzed in an animal model of depression, the olfactory bulbectomy (OBX) rats, the effect of GAL(1-15) on FLX-mediated responses in the forced swimming test and the sucrose preference test and the involvement of GAL receptor 2 with its antagonist, M871. We have also studied the corticosterone levels in OBX after the coadministration of GAL(1-15) with FLX. Moreover, we studied whether the effects of GAL(1-15) on FLX actions were mediated via auto- and heteroreceptor 5-HT1A (5-HT1AR), analyzing the binding characteristics, mRNA levels, and functionality of 5-HT1AR in the dorsal hippocampus. RESULTS: GAL(1-15) enhances the antidepressant-like effects induced by FLX in OBX animals in the forced swimming test and the sucrose preference test. The involvement of the GALR2 was demonstrated with M871. Importantly, the mechanism underlying the GAL(1-15)/FLX interactions in the OBX animals involves the 5-HT1AR in the hippocampus at the plasma membrane (increase of affinity and density of 5HT1AR in the DG) and transcriptional (increase of 5HT1AR mRNA levels in DG and CA1) levels. Besides, the coadministration of GAL(1-15) and FLX also reduced OBX-increased corticosterone levels. CONCLUSIONS: The results open the possibility to use GAL(1-15) in combination with FLX as a novel strategy for the treatment of depression.

Topics & Concepts

GalaninSerotonergicInternal medicineBehavioural despair testEndocrinologyCorticosteronePsychologyFluoxetineHippocampusAntidepressantOpen fieldSerotonin reuptake inhibitorHippocampal formationNeuroscienceNeuropeptideReceptorSerotoninBiologyMedicineHormoneNeuropeptides and Animal PhysiologyNerve injury and regenerationHypothalamic control of reproductive hormones